2096 (2096) Fair Value & Analysis
Healthcare · Market cap HK$27.7B
Fair value as of: Jul 2, 2026
From 26 valuation models · updated today
Share price +10.3% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$9.25 – HK$14.49 · fair‑value band HK$9.28 – HK$15.77 · the HK$10.79 price screens below the HK$12.80 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
2096 (2096) currently trades at HK$10.79, while our model-based Fair Value estimate is HK$12.80 — implying the stock looks roughly 18.6% undervalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, 2096 generated revenue of HK$7.7B at a net margin of 17.4%. Revenue grew 17.7% year over year. It earns a return on equity of 16.2%. The balance sheet holds a net cash position of HK$2.4B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
2096 reported revenue of HK$7.7B in FY2025 versus HK$5.0B in FY2021, a compound +11.5%/yr. Reported net income was HK$1.3B in FY2025, compounding −2.8%/yr from FY2021.
Is 2096 fairly valued? → Check now
Recent news
- Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients wi
- NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
- NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
- NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 2096 (2096) undervalued?
What is the fair value of 2096?
What is the quality score of 2096?
What is the revenue of 2096 (2096)?
What is the net profit margin of 2096?
Does 2096 pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.